Tibial Tubercle Distalisation and Accelerated Rehabilitation
Launched by TAMPERE UNIVERSITY HOSPITAL · May 2, 2023
Trial Information
Current as of November 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different rehabilitation approaches for patients with a specific knee condition called patella alta, which can cause knee pain and issues like dislocations. The trial aims to find out if a new, faster rehabilitation program can help patients recover more quickly and improve their knee function compared to the traditional, slower rehabilitation method after a surgical procedure known as tibial tubercle distalisation. Researchers will track patients’ recovery over six, twelve, and twenty-four weeks to see if the faster approach leads to better results and if the number of complications is similar in both groups.
To participate in this trial, individuals need to be between the ages of 15 and 35 and have been experiencing significant knee pain or dislocation issues that haven’t improved with regular rehabilitation. Those with certain knee joint problems, severe health issues, or who do not understand the instructions may not be eligible. Participants will be randomly assigned to either the fast or traditional rehabilitation program after their surgery, and they can expect regular check-ins to assess their recovery progress. If someone chooses not to join the trial, they will still be followed up with standard care while providing feedback on their experience.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic patella alta with recurrent dislocation or subluxation. Long-lasting anterior knee pain not responding to rehabilitation.
- Exclusion Criteria:
- Radiographic:
- • Open growth plates
- • Iwano \[8\] grade III and IV changes in patellofemoral joint
- • Caton-Deschamps \<1.1 in MRI
- • PTI \>50% in MRI
- • High grade trochlear dysplasia
- General:
- • Refuses to participate in the study
- • Aged less than 15 or more than 35 years
- • Severe neurological, pulmonal or cardiovascular comorbidities that are contraindications for surgery
- • Lack of adequate co-operation
- • Does not adequately understand written and spoken instructions in the local language
- • Those patients who decline to take part in the trial will be asked to join a follow-up cohort as a background population. The patients in this follow-up cohort will be treated "as normal" without allocation, but the follow-up questionnaires will be the same as those given to the randomly assigned population. The patients in the follow-up cohort will also be asked to provide informed written consent.
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Frederick Weitz
Study Chair
Pihlajalinna
Ville M Mattila, Prof
Study Chair
Department of Orthopaedic Surgery, Tampere University Hospital, Tampere, Finland
Erkki Nilkku
Study Chair
Pihlajalinna
Petri J Sillanpää
Study Chair
Pihlajalinna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported